PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23874242-5	2013	Lixivaptan is a newer, non-peptide, vasopressin type 2 receptor antagonist.	lixivaptan	0-10	arginine vasopressin	Homo sapiens	36-47
20973922-3	2010	Lixivaptan is a selective, oral vasopressin V(2) -receptor antagonist that improves hyponatremia by promoting electrolyte-free aquaresis without significant side effects.	lixivaptan	0-10	arginine vasopressin receptor 2	Homo sapiens	32-58
21548825-3	2011	Lixivaptan is a selective vasopressin type 2 (V(2)) receptor antagonist that has been demonstrated to have the ability to induce aquaresis, the electrolyte sparing excretion of water, resulting in fluid removal as well as correction of hyponatremia.	lixivaptan	0-10	arginine vasopressin	Homo sapiens	26-37
21046526-0	2010	Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.	lixivaptan	0-10	arginine vasopressin receptor 2	Homo sapiens	26-49
21046526-1	2010	Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia associated with heart failure.	lixivaptan	0-10	arginine vasopressin receptor 2	Homo sapiens	144-167
21046526-1	2010	Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia associated with heart failure.	lixivaptan	12-19	arginine vasopressin receptor 2	Homo sapiens	144-167
22932119-2	2012	Lixivaptan, a new selective vasopressin V2-receptor antagonist, safely corrected serum sodium concentrations in phase II studies of patients with euvolemic hyponatremia.	lixivaptan	0-10	arginine vasopressin receptor 2	Homo sapiens	28-51
22932122-4	2012	Here we evaluated the efficacy, safety, and tolerability of oral lixivaptan, a selective vasopressin V2-receptor antagonist, for treatment of nonhospitalized individuals with euvolemic hyponatremia (sodium less than 135 mmol/l) in a multicenter, randomized, double-blind, placebo-controlled, phase III study.	lixivaptan	65-75	arginine vasopressin receptor 2	Homo sapiens	89-112
19092365-7	2009	Tolvaptan, conivaptan, and lixivaptan are some of the vasopressin antagonists that have been studied in heart failure.	lixivaptan	27-37	arginine vasopressin	Homo sapiens	54-65
19379124-0	2009	Lixivaptan: a novel vasopressin receptor antagonist.	lixivaptan	0-10	arginine vasopressin	Homo sapiens	20-31
19379124-4	2009	Lixivaptan is a vasopressin receptor antagonist with high V2 receptor affinity and is now undergoing Phase III clinical trials.	lixivaptan	0-10	arginine vasopressin	Homo sapiens	16-27
11566011-1	2001	Lixivaptan is a non-peptide, orally-active vasopressin antagonist under development by American Home Products for the potential treatment of hyponatremia associated with diseases such as heart failure, liver cirrhosis and nephrotic syndrome.	lixivaptan	0-10	arginine vasopressin	Homo sapiens	43-54
16794787-4	2006	The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective activity (conivaptan) which may be advantageous in some disorders.	lixivaptan	90-100	arginine vasopressin	Homo sapiens	16-27
12395330-2	2002	VPA-985 is a selective, nonpeptide, orally active, vasopressin-2-receptor antagonist.	lixivaptan	0-7	arginine vasopressin	Homo sapiens	51-62
18306096-5	2008	The AVP-receptor antagonists, including conivaptan, tolvaptan, lixivaptan, and satavaptan, represent a therapeutic advance in the treatment of dilutional hyponatremia.	lixivaptan	63-73	arginine vasopressin	Homo sapiens	4-7
16630999-9	2006	CONCLUSIONS: These observations confirm a role for AVP in the renal water retention associated with heart failure and suggest that the V2 receptor antagonist lixivaptan may be a promising therapeutic agent for the treatment of heart failure.	lixivaptan	158-168	arginine vasopressin	Homo sapiens	51-54
12500203-0	2003	A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.	lixivaptan	35-42	arginine vasopressin	Homo sapiens	2-13
11433224-1	2001	VPA-985 is an orally active, competitive vasopressin V(2) receptor antagonist that in normal human beings increases water excretion without affecting solute excretion.	lixivaptan	0-7	arginine vasopressin receptor 2	Homo sapiens	41-66
10505693-7	1999	Compared to placebo, urinary AQP-2 excretion decreased significantly and in all groups in a dose-dependent manner during VPA-985 administration.	lixivaptan	121-128	aquaporin 2	Homo sapiens	29-34
9651149-0	1998	5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.	lixivaptan	108-115	arginine vasopressin	Homo sapiens	144-155
34486176-3	2021	Here we show that co-targeting two GPCRs, the vasopressin V2 receptor (V2R) and the calcium sensing receptor, using the novel V2R antagonist lixivaptan in combination with the calcimimetic R-568, reduced cyst progression in two animal models of human PKD.	lixivaptan	141-151	arginine vasopressin receptor 2	Homo sapiens	46-69
10026835-0	1998	VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.	lixivaptan	0-7	arginine vasopressin receptor 2	Homo sapiens	50-73
34486176-3	2021	Here we show that co-targeting two GPCRs, the vasopressin V2 receptor (V2R) and the calcium sensing receptor, using the novel V2R antagonist lixivaptan in combination with the calcimimetic R-568, reduced cyst progression in two animal models of human PKD.	lixivaptan	141-151	arginine vasopressin receptor 2	Homo sapiens	71-74
34486176-3	2021	Here we show that co-targeting two GPCRs, the vasopressin V2 receptor (V2R) and the calcium sensing receptor, using the novel V2R antagonist lixivaptan in combination with the calcimimetic R-568, reduced cyst progression in two animal models of human PKD.	lixivaptan	141-151	calcium sensing receptor	Homo sapiens	84-108
34486176-3	2021	Here we show that co-targeting two GPCRs, the vasopressin V2 receptor (V2R) and the calcium sensing receptor, using the novel V2R antagonist lixivaptan in combination with the calcimimetic R-568, reduced cyst progression in two animal models of human PKD.	lixivaptan	141-151	arginine vasopressin receptor 2	Homo sapiens	126-129
34486176-3	2021	Here we show that co-targeting two GPCRs, the vasopressin V2 receptor (V2R) and the calcium sensing receptor, using the novel V2R antagonist lixivaptan in combination with the calcimimetic R-568, reduced cyst progression in two animal models of human PKD.	lixivaptan	141-151	protein kinase D1	Homo sapiens	251-254
31888044-0	2019	Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells.	lixivaptan	0-10	aquaporin 2	Homo sapiens	71-82
34486176-4	2021	Lixivaptan is expected to have a safer liver profile compared to tolvaptan, the only drug approved to delay PKD progression, based on computational model results and initial clinical evidence.	lixivaptan	0-10	protein kinase D1	Homo sapiens	108-111
31888044-5	2019	Here, the effect of lixivaptan-a novel selective V2R antagonist-on the vasopressin-cAMP/PKA signaling cascade was investigated in mouse renal collecting duct cells expressing AQP2 (MCD4) and the human V2R.	lixivaptan	20-30	arginine vasopressin receptor 2	Mus musculus	49-52
31888044-7	2019	In MCD4 cells, clinically relevant concentrations of lixivaptan (100 nM for 1 h) prevented dDAVP-induced increase of cytosolic cAMP levels and AQP2 phosphorylation at ser-256.	lixivaptan	53-63	phosphatidylinositol glycan anchor biosynthesis class N	Homo sapiens	3-7
31888044-7	2019	In MCD4 cells, clinically relevant concentrations of lixivaptan (100 nM for 1 h) prevented dDAVP-induced increase of cytosolic cAMP levels and AQP2 phosphorylation at ser-256.	lixivaptan	53-63	aquaporin 2	Homo sapiens	143-147
31888044-9	2019	These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention.	lixivaptan	118-128	aquaporin 2	Homo sapiens	77-81
31117065-2	2019	In this study, the effect of lixivaptan, a potent, selective vasopressin V2 antagonist, was evaluated in PCK rats, a validated animal model of PKD.	lixivaptan	29-39	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	105-108
31117065-7	2019	Compared to controls, PCK rats treated with low-dose lixivaptan showed a 26% reduction in % kidney weight/body weight (p < 0.01); a 54% reduction in kidney cystic score (p < 0.001), a histomorphometric measure of cystic burden; a 23% reduction in kidney cAMP levels (p < 0.05), a biochemical marker of disease; and a 13% reduction in plasma creatinine (p < 0.001), indicating preserved renal function.	lixivaptan	53-63	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	22-25